186 related articles for article (PubMed ID: 18510642)
21. Update on the clinical pharmacogenomics of organ transplantation.
Burckart GJ; Amur S
Pharmacogenomics; 2010 Feb; 11(2):227-36. PubMed ID: 20136361
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
23. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
24. Thiopurine S-methyltransferase polymorphism in Iranian kidney transplant recipients.
Aghdaie MH; Azarpira N; Geramizadeh B; Sagheb M; Darai M; Rahsaz M; Malekhoseini SA
Exp Clin Transplant; 2011 Aug; 9(4):241-6. PubMed ID: 21819368
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
van Gelder T; van Schaik RH; Hesselink DA
Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
[TBL] [Abstract][Full Text] [Related]
26. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
Picard N; Marquet P
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):731-43. PubMed ID: 21434840
[TBL] [Abstract][Full Text] [Related]
27. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
28. PharmGKB summary: cyclosporine and tacrolimus pathways.
Barbarino JM; Staatz CE; Venkataramanan R; Klein TE; Altman RB
Pharmacogenet Genomics; 2013 Oct; 23(10):563-85. PubMed ID: 23922006
[No Abstract] [Full Text] [Related]
29. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy.
Cattaneo D; Perico N; Remuzzi G
Am J Transplant; 2004 Mar; 4(3):299-310. PubMed ID: 14961981
[TBL] [Abstract][Full Text] [Related]
30. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
31. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics in solid organ transplantation: current status and future directions.
de Jonge H; Kuypers DR
Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
Coto E; Tavira B
Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
[TBL] [Abstract][Full Text] [Related]
34. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
35. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.
Calabrese DR; Florez R; Dewey K; Hui C; Torgerson D; Chong T; Faust H; Rajalingam R; Hays SR; Golden JA; Kukreja J; Singer JP; Greenland JR
Clin Transplant; 2018 Aug; 32(8):e13332. PubMed ID: 29920787
[TBL] [Abstract][Full Text] [Related]
36. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Zhu J; Patel T; Miller JA; Torrice CD; Aggarwal M; Sketch MR; Alexander MD; Armistead PM; Coghill JM; Grgic T; Jamieson KJ; Ptachcinski JR; Riches ML; Serody JS; Schmitz JL; Shaw JR; Shea TC; Suzuki O; Vincent BG; Wood WA; Rao KV; Wiltshire T; Weimer ET; Crona DJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013193
[TBL] [Abstract][Full Text] [Related]
37. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics.
Christians U; Strom T; Zhang YL; Steudel W; Schmitz V; Trump S; Haschke M
Ther Drug Monit; 2006 Feb; 28(1):39-44. PubMed ID: 16418692
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
39. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
